Clinical trials: Lymphomas,
Acute Lymphoblastic Leukemia
Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia
Studies in the 1970s and 1980s suggested that the outcome of childhood acute lymphoblastic leukemia could be improved by intensification of conventional continuation chemotherapy with pulses of vincristine sulfate and steroids.
- Trial name
- NCT00411541
- Testing
- vincristine, dexamethasone
- Where
- 8 sites in Argentina, Austria and 6 more
- Volunteers
- 2,600 people
- Sponsor
- International BFM Study Group
Mantle Cell Lymphoma
Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.
This is a single arm, open label, national multicenter clinical study included patients with relapsed and refractory blastoid variant of mantle cell lymphoma (R/R BV-MCL), aiming to evaluate the efficacy of a chemotherapy free…
- Trial name
- NCT06324994
- Testing
- Linperlisib in combination with Obinutuzumab and Venetoclax
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Dalian Medical University
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT
Chronic Graft Versus Host Disease (GVHD) is one of the most challenging complications in long term survivors of allogeneic stem cell transplantation.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT03066466
- Testing
- Atorvastatin, Methotrexate, Tacrolimus
- Where
- United States
- Sponsor
- Loyola University
Hodgkin Lymphoma
A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma
The main aim is to check how effective BV is for treating adults with HL. Study medication will be prescribed according to the clinic's standard practice. Participants will visit the study clinic 5 times, once every 12 weeks.
- Trial name
- BV-MAZOVIA (NCT05100056)
- Testing
- No Intervention
- Where
- 13 sites in Poland
- Volunteers
- 70 people
- Sponsor
- Takeda
Breast Cancer (Triple Negative Breast Cancer (TNBC)), Renal Cell Carcinoma (Kidney Cancer)
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and work by blocking protein interactions that normally prevent the immune system from recognizing and destroying cancer cells.
- Conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC)), Renal Cell Carcinoma (Kidney Cancer), Melanoma (Skin Cancer), Non-Small Cell Lung Cancer
- Trial name
- NCT07555210
- Testing
- Dual-Energy X-ray Absorptiometry (DXA), High Resolution peripheral Quantitative Computed Tomography (HRpQCT)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Jessica Mezzanotte Sharpe
Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma
Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)
This Phase I study will evaluate the safety of autologous Epstein-Barr virus-specific T lymphocytes modified to express a constitutively active IL7 receptor (C7R) and a chimeric antigen receptor (CAR) for CD30…
- Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma, ALK-Positive
- Trial name
- ANCILE-30 (NCT07729397)
- Testing
- Autologous C7R.CD30-CAR-EBVSTs
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- The Methodist Hospital Research Institute
Large B-cell Lymphoma, Follicular Lymphoma
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel
The goal of this study is to provide access to axicabtagene ciloleucel for patients diagnosed with a disease approved for treatment with axicabtagene ciloleucel, that is otherwise out of specification for commercial release.
- Trial name
- NCT05776160
- Testing
- Axicabtagene Ciloleucel
- Where
- 128 sites in United States, Japan
- Sponsor
- Kite, A Gilead Company
B-cell Non-Hodgkin's Lymphoma
Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma
A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human CD19 Targeted T Cells Injection (CD19 CAR-T) Therapy for R/R B-NHL.
- Trial name
- NCT05436223
- Testing
- Human CD19Targeted T Cells Injection
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Mediastinal Lymphadenopathy, Hilar Lymphadenopathy
Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration for the Diagnosis of Hilar/Mediastinal Lymphadenopathies
The main purpose of the present study is to assess whether the sensitivity of Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) is superior to that of conventional TBNA in the diagnosis of hilar/mediastinal…
- Conditions
- Mediastinal Lymphadenopathy, Hilar Lymphadenopathy, Lymphoma, Lung Neoplasms
- Trial name
- NCT01658280
- Testing
- EBUS-TBNA
- Where
- Italy
- Volunteers
- 253 people
- Sponsor
- Azienda Ospedaliero, Universitaria Ospedali Riuniti
Classical Hodgkin Lymphoma
Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
This was a Phase 2 trial evaluating the effectiveness and safety of tislelizumab in participants with relapsed or hard-to-treat classical Hodgkin lymphoma (cHL). Participants were grouped by prior treatments.
- Trial name
- TIRHOL (NCT04318080)
- Testing
- Tislelizumab
- Where
- 4 sites in United States, Australia
- Volunteers
- 46 people
- Sponsor
- BeiGene
Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma
Efficacy of Lenalidomide Maintenance in Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma: a Phase II, Open-label, Single-arm Study
Therefore, we intend to conduct a phase II study to evaluate the efficacy of maintenance therapy with lenalidomide as the maintenance therapy for patients with PCNSL or PVRL who have achieved CR or partial response after…
- Trial name
- NCT05901324
- Testing
- intensity-modulated radiotherapy (IMRT)
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
ARDS (Moderate or Severe), Prone Position
The PRE-VAIL Study
During the prone position, there may be an increase in intragastric pressure. The investigators focus on a scientific question: Whether reducing enteral nutrition before the prone position will benefit patients with severe…
- Conditions
- ARDS (Moderate or Severe), Prone Position, Enteral Nutrition Feeding, Intensive Care Unit (ICU) Admission
- Trial name
- NCT07176624
- Testing
- Enteral nutrition is reduced before the prone position
- Where
- China
- Volunteers
- 259 people
- Sponsor
- The First Hospital of Jilin University
Peripheral T Cells Lymphoma (PTCL)
Polyspecific Antibodies in Lymphoproliferative T-cell Disorders
This is a 2-part study consisting of a Part 1, dose escalation and dose-finding component to establish the Maximal Tolerated Dose (MTD), or Recommended Part 2 Dose (RP2D) of LIS1 as a single agent; followed by a Part 2, to…
- Trial name
- PALT1 (NCT06495723)
- Testing
- LIS1
- Where
- 8 sites in France, Italy
- Volunteers
- 54 people
- Sponsor
- Xenothera SAS
EBV-Related Hodgkin Lymphoma, EBV-Related Lymphoproliferative Disorder
EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
This study is for patients that have a type of lymph gland disease called Hodgkin or non-Hodgkin Lymphoma or T/NK-lymphoproliferative disease which has come back or has not gone away after treatment, including the best treatment…
- Conditions
- EBV-Related Hodgkin Lymphoma, EBV-Related Lymphoproliferative Disorder, EBV Related Non-Hodgkin's Lymphoma
- Trial name
- CILESTE (NCT04664179)
- Testing
- Dose Level 1A: 2 x 10^7 cells/m2, Dose Level 2A: 6 x 10^7 cells/m2, Dose Level 2B: 6 x 10^7 cells/m2
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Baylor College of Medicine
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia
This is a small-scale micro-randomized clinical trial of a new mobile just-in-time adaptive intervention (JITAI) designed to promote oral chemotherapy adherence in adolescents and young adults (AYA) with acute lymphoblastic…
- Trial name
- NCT03932903
- Testing
- ADAPTS (ADherence Assessments and Personalized Timely Support).
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Northwestern University
Non Hodgkin Lymphoma
Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line Therapy
A phase II prospective, non-randomized study. The study aim is to evaluate the feasibility and activity of high-dose therapy with stem cell in elderly patients with aggressive lymphoma relapsed FIT or resistant to first line…
- Trial name
- NCT02371161
- Testing
- R-DHAP/R-ICE
- Where
- 27 sites in Italy
- Volunteers
- 135 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Adult ALL
Virtual Reality-Infused Treadmill Training on Aging-Related Outcomes
Age-associated motor and cognitive deficits increase the risk of falls, a major cause of morbidity and mortality. Emerging evidence suggests that inflammatory mediators lead to impaired functional capacity and frailty in the…
- Trial name
- V-TARGET (NCT06727942)
- Testing
- V-TARGET intervention
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- The University of Texas at Arlington
Hodgkin Lymphoma
Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma
The primary objective is to estimate the efficacy of experimental treatment with the anti-PD-1 antibody cemiplimab (REGN2810) in combination with simultaneous or subsequent radiotherapy (RT) in early-stage favorable classical…
- Trial name
- NCT04373083
- Testing
- Cemiplimab, Involved-site radiotherapy (IS-RT)
- Sponsor
- Regeneron Pharmaceuticals
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)
This phase II MATCH treatment trial identifies the effects of dasatinib in patients whose cancer has a genetic change called DDR2 mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439305
- Testing
- Dasatinib
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia
LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive
Due to ALL Ph+ patients should receive a different treatment, is proposed a therapeutical protocol with: intensification treatment of induction to increment the CR rate, allogenic transplantation in first CR, autologous…
- Trial name
- NCT00526305
- Testing
- Vincristine, Daunorubicin, Prednisone
- Where
- 50 sites in Spain
- Volunteers
- 100 people
- Sponsor
- PETHEMA Foundation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.